Apple has made use of this unique metal extensively in the new iPhone describing it as having "one of the best strength-to-weight ratios of any metal". It's not just Apple though, with applications in aerospace, defense, and medical devices, titanium has become essential...Unfortunately, 90% of the supply is controlled by adversarial nations meaning a supply disruption would have paralyzing effects on daily life in the US.
|
|
| A message from our valued partners and today's trending news. | | | |
|
| Savvy Investors Notice "Wonder Metal" in iPhone - Ad
Apple has made use of this unique metal extensively in the new iPhone describing it as having "one of the best strength-to-weight ratios of any metal". It's not just Apple though, with applications in aerospace, defense, and medical devices, titanium has become essential...Unfortunately, 90% of the supply is controlled by adversarial nations meaning a supply disruption would have paralyzing effects on daily life in the US. More Info ➔ | This is a paid advertisement sent on behalf of i2i Marketing Group, LLC. Musth Corp receives a fixed fee for each subscriber that clicks on a link in this email. See our disclaimer for further details on compensation, affiliation and ethics. | | | | | Super-Billionaire Goes All-in on $3 A.I. Stock - Ad
I've been pounding the table on this $3 A.I. stock for weeks now. I believe we'll soon talk about this little-known stock in the same way we talk about Amazon, Tesla, and Nvidia now. This is without a doubt my #1 recommendation to buy today. More Info ➔ | | | | | | A 10,000% Dividend?!? - Ad
Have you seen this strange oil investment? It's NOT a stock, bond, or private company...It has NO age requirements...You do NOT need to be accredited to participate... And you can get in for as little as $25. More Info ➔ | | | | | | Why Is Cancer Drug-Developer Nkarta Stock Trading Lower On Friday?
Nkarta closed patient enrollment in NKX101 clinical trial, reallocating focus to lead program NKX019 for autoimmune disease. Recent expansion into autoimmune disease with FDA clearance for NKX019 in lupus nephritis signals company growth. Financially sound with $250.9 million in cash, expected to sustain operations through 2026. More Info ➔ | | | | | | |
| Information, charts or examples contained in this email are for illustration and educational purposes only and not for individualized investment management. This message contains commercial elements, such as advertising as well as partner offers for which we may receive affiliate compensation. We only send these offers to those who have opted in to our newsletter. If you wish to no longer receive these offers click on the unsubscribe link at the bottom of this email. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained in this email or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.
339-20 De Boers Dr., Toronto, ON M3J 0H1, 917.672.7040 © 2024 Musth | TrendAdvisor | All rights reserved.
Unsubscribe | | | | |
No comments:
Post a Comment